Endometrial Response in Polycystic Ovarian Syndrome Treated With Letrozole Alone or With Added Estradiol Valerate

Starting soon · Not applicable

Conditions studied: PCOS (Polycystic Ovary Syndrome)

In brief

Polycystic Ovary Syndrome (PCOS) is one of the most common endocrine disorders among women of reproductive age, characterized by chronic anovulation, hyperandrogenism, and polycystic ovarian morphology. Letrozole, an aromatase inhibitor, has emerged as a first-line ovulation induction agent due to its superior ovulation and pregnancy rates compared to clomiphene citrate. Estradiol valerate, a synthetic estrogen, can be co-administered with letrozole to improve endometrial receptivity by enhancing endometrial thickness, vascularity, and pattern. This study aims to evaluate the effect of letrozole alone versus letrozole with estradiol valerate on endometrial development in these patients.

Key facts

Study ID

NCT07379502

Run by

CMH Kharian Medical College

People needed

60

Starts

2026-03-05

Expected to finish

2026-08-31

Last updated by the study team

2026-01-30

Who can join

Age: 20 and older, up to 35. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Women aged 20-35 years
• Clinical diagnosis of PCOS (Rotterdam criteria)

You may not qualify if…

• Endocrine disorders other than PCOS
• Endometrial pathology or uterine malformations
• Allergy to letrozole or estradiol
• Hormonal therapy within last 3 months

Where it is running

• CMH Kharian Medical College — Khārian, Punjab Province, Pakistan

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.